Lipitor Lawsuits Move Forward in Federal Litigation with Issuance of New Order in South Carolina, Bernstein Liebhard LLP Reports

Share Article

The Firm is actively filing Lipitor lawsuits on behalf of individuals who allegedly developed Type 2 diabetes after taking the cholesterol-lowering statin.

Free Case Review
Our Firm’s attorneys continue to hear from women who were allegedly injured by the cholesterol-lowering statin.

A federal judge presiding over Lipitor lawsuits ( in the U.S. District Court, District of South Carolina has issued a new Order that will streamline the process for filing cases in the multidistrict litigation, Bernstein Liebhard LLP reports.

According to a Case Management Order dated June 2, 2014, the Court approved use of a Master Complaint and Short Form Complaint in the federal proceeding, which includes cases over the statin medication used to treat patients with high cholesterol. A Case List updated on May 15th shows at least 703 lawsuits alleging new-onset diabetes caused by Lipitor, which is manufactured and distributed by Pfizer, Inc., filed in the multidistrict litigation. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)

“We are pleased to see further progress in the federal litigation involving Lipitor lawsuits, as our Firm’s attorneys continue to hear from women who were allegedly injured by the cholesterol-lowering statin,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs including Lipitor. The Firm is currently offering free and confidential case reviews to individuals who may have been harmed by this medication.

Lipitor Lawsuits
Included in more than 700 Lipitor lawsuits now filed in the U.S. District Court, District of South Carolina are allegations that use of the medication may increase a patient’s likelihood of developing Type 2 diabetes, court documents indicate. These claims are continuing to move forward in the jurisdiction, where a federal multidistrict litigation was established in February 2014. According to recent records, the Lipitor litigation has begun the process for selecting cases for its first bellwether trials, which are likely to begin on or after July 1, 2015.

Court documents indicate that Lipitor diabetes claims have continued to mount since January 2012, when research published in JAMA: Internal Medicine lent evidence to the possibility that post-menopausal women taking Lipitor may be at increased risk for developing Type 2 diabetes.* A month later, the U.S. Food and Drug Administration (FDA) mandated that all statin manufacturers adjust their product labeling to highlight their possible association with the disease. Plaintiffs in Lipitor lawsuits challenge its new diabetes warnings, however, in allegations that Pfizer continues to provide inadequate warning about this side effect, according to court records.

Alleged victims of Lipitor and diabetes may be eligible to receive compensation for medical bills, lost wages, and pain and suffering they may have been caused as a result of the medication. Find out more about Lipitor and diabetes by visiting Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.

*, JAMA Internal Medicine, January 2012

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993? As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website